MediWound (MDWD) Competitors $20.03 -1.06 (-5.03%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$20.02 -0.01 (-0.02%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDWD vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYREShould you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. MediWound vs. Its Competitors Oculis Chimerix Avid Bioservices uniQure CorMedix Cronos Group GH Research Syndax Pharmaceuticals Immunome Gyre Therapeutics MediWound (NASDAQ:MDWD) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Does the media prefer MDWD or OCS? In the previous week, Oculis had 2 more articles in the media than MediWound. MarketBeat recorded 4 mentions for Oculis and 2 mentions for MediWound. MediWound's average media sentiment score of 1.35 beat Oculis' score of 0.47 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is MDWD or OCS more profitable? MediWound has a net margin of -110.45% compared to Oculis' net margin of -13,788.70%. MediWound's return on equity of -74.12% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets MediWound-110.45% -74.12% -30.92% Oculis -13,788.70%-92.95%-70.03% Do analysts recommend MDWD or OCS? MediWound currently has a consensus target price of $31.80, indicating a potential upside of 58.76%. Oculis has a consensus target price of $35.33, indicating a potential upside of 95.64%. Given Oculis' higher possible upside, analysts plainly believe Oculis is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in MDWD or OCS? 46.8% of MediWound shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable valuation & earnings, MDWD or OCS? MediWound has higher revenue and earnings than Oculis. MediWound is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$20.22M10.71-$30.22M-$2.09-9.58Oculis$780K1,010.90-$97.43M-$2.64-6.84 Which has more risk & volatility, MDWD or OCS? MediWound has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. SummaryMediWound beats Oculis on 11 of the 15 factors compared between the two stocks. Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDWD vs. The Competition Export to ExcelMetricMediWoundMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.93M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-9.589.4228.0520.27Price / Sales10.71714.12429.5999.27Price / CashN/A165.3637.4658.16Price / Book6.934.608.055.49Net Income-$30.22M$31.26M$3.18B$250.45M7 Day Performance2.88%4.80%3.60%4.77%1 Month Performance-1.57%5.42%4.03%7.66%1 Year Performance-5.34%-4.36%29.49%16.39% MediWound Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDWDMediWound1.8463 of 5 stars$20.03-5.0%$31.80+58.8%-0.3%$227.93M$20.22M-9.5880Positive NewsOCSOculis2.2152 of 5 stars$18.74-1.4%$35.33+88.5%+58.4%$829.59M$780K-7.102News CoverageCMRXChimerix0.5513 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6186 of 5 stars$12.50+0.1%$12.25-2.0%+56.2%$799.18M$139.91M-5.23320News CoverageHigh Trading VolumeQUREuniQure2.7264 of 5 stars$14.31-0.8%$37.82+164.3%+61.6%$789.86M$27.12M-3.26500CRMDCorMedix2.7322 of 5 stars$11.42-1.7%$17.14+50.1%+128.5%$788.13M$82.55M51.9130CRONCronos Group1.5793 of 5 stars$2.04flatN/A-12.2%$786.79M$117.61M15.69450News CoverageGHRSGH Research1.9874 of 5 stars$15.01+0.7%$32.00+113.2%+33.4%$776MN/A-19.0010SNDXSyndax Pharmaceuticals3.0319 of 5 stars$8.73-3.0%$35.80+310.1%-59.2%$774.43M$23.68M-2.26110Analyst ForecastIMNMImmunome2.0935 of 5 stars$8.69-1.7%$23.33+168.5%-33.4%$769.19M$9.04M-2.7340Positive NewsGYREGyre Therapeutics0.2315 of 5 stars$7.62-6.3%N/A-40.6%$762.25M$105.76M381.1940Positive News Related Companies and Tools Related Companies Oculis Alternatives Chimerix Alternatives Avid Bioservices Alternatives uniQure Alternatives CorMedix Alternatives Cronos Group Alternatives GH Research Alternatives Syndax Pharmaceuticals Alternatives Immunome Alternatives Gyre Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDWD) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
